Showing 5661-5670 of 8819 results for "".
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Allergan to Acquire ZELTIQ for $2.47 Billionhttps://practicaldermatology.com/news/allergan-to-acquire-zeltiq-for-247-billion/2458291/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggresso
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the Natio
- Cochrane Review: All Moisturizers Created Equally for Eczemahttps://practicaldermatology.com/news/cochrane-review-all-moisturizers-created-equally/2458292/No one moisturizer is better than another when it comes to relieving the symptoms of eczema, according to a new Cochrane Review. Overall, most moisturizers show beneficial effects for eczema, work bet
- Alma Lasers' Accent Celebrates 10 Years with a New Campaignhttps://practicaldermatology.com/news/alma-lasers-accent-celebrates-10-years-with-a-new-campaign/2458294/Accent Prime is celebrating a 10 year anniversary with a newly launched campaign. Alma Lasers released the first generation of the Accent branded platform in 2007, with the FDA approval, and technologically enhanced it throughout the pas
- Study Finds Increased Incidence of SCC Among Patients Treated with Biologics for Psoriasishttps://practicaldermatology.com/news/study-find-increased-incidence-of-scc-among-patients-treated-with-biologics-for-psoriasis/2458296/A recent study published in the Journal of the American Academy of Dermatology sought to estimate the overall malignancy rate (excluding non-melanoma skin cancere [NMSC]) and NMSC rate among 5,889 patients with systemically
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only